Showing 2877 results
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Press release /
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED…
Pagination
- ‹ Previous page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- …
- 288
- › Next page